Mark Hyman, MD · 2026-07-01 · Mark Hyman (host), Cindy Geyer, Aseem Malhotra, Eric Topol

It's Not Cholesterol. Inflammation Is What's Actually Causing Heart Disease

48 research-tied claims examined: 6 contradicted 6 overstated 1 context 34 supported 1 unverified

Contradicted by research

Small HDL particles are less capable of clearing LDL particles and facilitating reverse cholesterol transport than larger HDL particles.

"The same is true for HDL. We've historically thought of HDL as being the good, healthy cholesterol, but size matters there, too. Small HDL doesn't seem to be as able to cart out the bad LDL and get rid of it." (said at 0:10:12)

The speaker states the relationship between HDL particle size and cholesterol removal backwards. In reverse cholesterol transport, small, dense HDL particles (such as discoidal HDL and pre-beta HDL) are the primary and most potent mediators of cellular cholesterol efflux via the ABCA1 (ATP-binding cassette transporter A1) pathway. Experimental and clinical studies consistently demonstrate that cholesterol efflux capacity increases as HDL particle size decreases, with small HDL particles displaying 3- to 5-fold greater efflux capacity than larger HDL subfractions.

contradicts: Flipped C-Terminal Ends of APOA1 Promote ABCA1-Dependent Cholesterol Efflux by Small HDLs. (Circulation 2024) · cited 37x in the literature
"In both the LCAT-deficient subjects and control subjects, the CEC of isolated extra-small HDL (a mixture of extra-small and small HDL by calibrated ion mobility analysis) was 3- to 5-fold greater than that of the larger sizes of isolated HDL. Incubating LCAT-deficient plasma and control plasma with human LCAT converted extra-small and small HDL particles into larger particles, and it markedly inhibited CEC." (abstract, results, passage verified)
pubmed full study (doi)
contradicts: Distinct roles of size-defined HDL subpopulations in cardiovascular disease. (Current opinion in lipidology 2025) · cited 10x in the literature
"Small HDL particles are more effective than larger particles at promoting cellular cholesterol efflux because apolipoprotein A-I on their surface better engages ABCA1 (ATP binding cassette subfamily A member 1)." (abstract, results, passage verified)
pubmed full study (doi)

0:12:45 Mark Hyman (host)contradictedhigh

The JUPITER trial and related studies showed that patients with high LDL cholesterol but low C-reactive protein have a negligible risk of cardiovascular disease compared to those with both high LDL and high CRP.

"A lot of the follow-up studies, like the JUPITER trial, they found that if patients had a high LDL but they didn't have a high CRP, their risk of heart disease was negligible. But if they had a high LDL and a high CRP, that was the problem." (said at 0:12:45)

The speaker misrepresents both the design of the JUPITER trial and the findings of studies evaluating LDL cholesterol and C-reactive protein (CRP). The JUPITER trial (Ridker et al., 2008) specifically enrolled individuals with low/normal LDL cholesterol (<130 mg/dL) and elevated hs-CRP (≥2.0 mg/L) to evaluate statin therapy in low-cholesterol, high-inflammation individuals; it did not evaluate participants with high LDL and low CRP. Furthermore, large cohort studies examining both biomarkers (such as Ridker et al., 2002) demonstrate that baseline LDL cholesterol and hs-CRP are independently and linearly associated with cardiovascular event risk; cardiovascular risk in individuals with high LDL cholesterol is not 'negligible' even when CRP levels are low.

contradicts: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the pre… (The New England journal of medicine 2002) · cited 3619x in the literature
"Although C-reactive protein and LDL cholesterol were minimally correlated (r=0.08), base-line levels of each had a strong linear relation with the incidence of cardiovascular events... screening for both biologic markers provided better prognostic information than screening for either alone." (abstract, results)
pubmed full study (doi)
contradicts: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. (The New England journal of medicine 2008) · cited 6700x in the literature
"Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment. We randomly assigned 17,802 apparently healthy men and women with low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to rosuvastatin, 20 mg daily, or placebo" (abstract, methods, passage verified)
pubmed full study (doi)

0:47:11 Aseem Malhotracontradictedmoderate

In the Framingham Heart Study data summarized by William Castelli in 1996, LDL cholesterol was useless as a predictor of coronary artery disease unless LDL was above ~7.8 mmol/L (~250 mg/dL).

"William Castelli is a cardiologist, and he published—uh, he was a co-director of Framingham, and in 1996 he published in one of the cardiology, major cardiology journals, a summary of Framingham specifically looking at LDL cholesterol. ... And he said from Framingham, unless your LDL was above 7.8, 8 millimoles, which by the way, I think in your units is probably 250 or 300, 250 probably. ... It absolutely had no—it was useless as a predictor for coronary artery disease." (said at 0:47:11)

In his 1996 review summarizing Framingham Heart Study insights on lipid risk factors, William Castelli did not state that LDL cholesterol was useless as a predictor of coronary artery disease below ~7.8 mmol/L (~300 mg/dL). Rather, Castelli identified abnormal lipids (including atherogenic low-density lipoproteins) as one of the three primary cardiovascular risk factors, while noting that because most coronary heart disease events occur in individuals with average total cholesterol levels (overlap between cases and non-cases), assessing isolated total cholesterol or LDL without HDL is insufficient. He advocated for using the total cholesterol-to-HDL cholesterol ratio and triglyceride levels to more effectively identify patients at high risk who require treatment.

contradicts: Lipids, risk factors and ischaemic heart disease. (Atherosclerosis 1996) · cited 327x in the literature
"Among these, the three most important are (1) abnormal lipids, including the fact that there are more than 15 types of cholesterol-containing lipoproteins and four different types of triglyceride-rich particles, some of which are very atherogenic, (2) high blood pressure, and (3) cigarette smoking... Firstly, the ratio of total cholesterol to high density cholesterol (HDL cholesterol) should be determined, followed by measurement of plasma triglyceride concentrations. This will allow differentiation of whether the low density lipoproteins (LDL), HDL cholesterol or triglyceride-rich particles such as the small dense beta-very low density lipoproteins (VLDL) are the major cause for concern." (abstract, results, passage verified)
pubmed full study (doi)

0:48:10 Aseem Malhotracontradictedhigh

When corrected for triglyceride and HDL levels, LDL cholesterol loses statistical significance as a predictor of heart disease.

"When you correct for triglycerides and HDL, okay, which by the way is a more important predictor of heart disease, LDL loses its significance completely." (said at 0:48:10)

Large-scale prospective cohort studies and individual-participant meta-analyses demonstrate that LDL cholesterol (LDL-C) and atherogenic apoB-containing particles remain statistically significant, independent predictors of coronary heart disease (CHD) after multivariable adjustment for HDL cholesterol and triglycerides. In the Emerging Risk Factors Collaboration analysis of 302,430 individuals across 68 prospective studies, directly measured LDL-C remained significantly associated with CHD risk even after adjustment for conventional risk factors including HDL-C and triglycerides (hazard ratio 1.38 per 1-SD increase, 95% CI 1.09–1.73). In fact, the inverse of the guest's claim occurred for triglycerides: after adjusting for HDL-C and non-HDL-C/LDL-C, triglycerides lost independent statistical significance for CHD (adjusted HR 0.99, 95% CI 0.94–1.05).

contradicts: Major lipids, apolipoproteins, and risk of vascular disease. (JAMA 2009) · cited 2789x in the literature
"Adjusted HRs for CHD were 0.99 (95% CI, 0.94-1.05) with triglyceride, 0.78 (95% CI, 0.74-0.82) with HDL-C, and 1.50 (95% CI, 1.39-1.61) with non-HDL-C... For the subset with apolipoproteins or directly measured LDL-C, HRs were 1.50 (95% CI, 1.38-1.62) with the ratio non-HDL-C/HDL-C, 1.49 (95% CI, 1.39-1.60) with the ratio apo B/apo AI, 1.42 (95% CI, 1.06-1.91) with non-HDL-C, and 1.38 (95% CI, 1.09-1.73) with directly measured LDL-C." (abstract, results)
pubmed full study (doi)

0:56:58 Mark Hyman (host)contradictedhigh

In the JUPITER trial, individuals with high LDL cholesterol but low inflammatory markers had lower cardiovascular risk than those with both high LDL and high inflammation.

"In fact, Paul Ridker from Harvard, I remember he published a trial, I think it was the JUPITER trial, where they showed that if you had a high LDL but didn't have any inflammation, you didn't have that significant a risk of having heart disease. But if you had a high level of inflammation, high LDL, you had a much higher risk." (said at 0:56:58)

The host's description of the JUPITER trial is contradicted by the trial's actual inclusion criteria and design. The JUPITER trial, led by Paul Ridker, specifically enrolled individuals with low-to-modest LDL cholesterol (<130 mg/dL) and elevated high-sensitivity C-reactive protein (hs-CRP ≥2 mg/L). The study did not evaluate or include patients with high LDL cholesterol and low inflammatory markers, and therefore did not demonstrate that high LDL in the absence of inflammation carries low cardiovascular risk.

contradicts: Baseline characteristics of participants in the JUPITER trial, a randomized placebo-contro… (The American journal of cardiology 2007) · cited 125x in the literature
"The Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) is a randomized, double-blind, placebo-controlled primary prevention trial of statin therapy among persons with average to low levels of low-density lipoprotein (LDL) cholesterol who are at increased cardiovascular risk due to elevated plasma concentrations of the inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP). A total of 17,802 persons with LDL cholesterol<130 mg/dl (3.36 mmol/L) and hs-CRP>or=2 mg/L were recruited" (abstract, background, passage verified)
pubmed full study (doi)
contradicts: Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes … (The American journal of cardiology 2010) · cited 159x in the literature
"random allocation of rosuvastatin compared to placebo among primary prevention patients with a low-density lipoprotein cholesterol level of <130 mg/dl and a high-sensitivity C-reactive protein (hs-CRP) level of > or =2 mg/L resulted in a highly significant 44% reduction in major vascular events." (abstract, results, passage verified)
pubmed full study (doi)

0:42:30 Aseem Malhotracontradictedhigh

The World Health Organization officially declared obesity a global epidemic in 2004.

"So 2004, WHO announced it as an epidemic." (said at 0:42:30)

The World Health Organization (WHO) officially recognized and declared obesity as a global epidemic in June 1997 during the WHO Consultation on Obesity in Geneva, rather than in 2004. The conclusions and recommendations of this landmark meeting were published in the WHO Technical Report Series under the title "Obesity: preventing and managing the global epidemic" (PMID 11234459). While the World Health Assembly adopted the Global Strategy on Diet, Physical Activity and Health in 2004, the formal declaration of the obesity epidemic itself occurred seven years earlier.

contradicts: Obesity: preventing and managing the global epidemic. Report of a WHO consultation. (World Health Organization technical report series 2000) · cited 13257x in the literature
"Obesity: preventing and managing the global epidemic. Report of a WHO consultation." (abstract, title, passage verified)
pubmed

Overstated

0:27:20 Eric Topoloverstatedmoderate

Artificial intelligence analysis of retinal photographs can predict the onset of Alzheimer's disease 5 to 7 years in advance.

"You can do a retina AI exam. So I have a picture of the retina and you do AI on it, and it tells you when you're going to have Alzheimer's, if you're going to have Alzheimer's 5 to 7 years in advance." (said at 0:27:20)

Large prospective cohort studies (including data from the UK Biobank) demonstrate that artificial intelligence and deep-learning models applied to retinal photographs or optical coherence tomography can identify retinal structural features and biological aging markers associated with an increased relative risk of developing Alzheimer's disease or dementia years (e.g., 5 to 12 years) before clinical diagnosis. However, framing this as a ready clinical exam that deterministically "tells you when you're going to have Alzheimer's, if you're going to have Alzheimer's" significantly overstates the evidence. Current AI retinal models quantify statistical risk and biological vulnerability in research cohorts; they are not clinically diagnostic or deterministic prognostic tests for individual patients.

partial: A deep-learning retinal aging biomarker for cognitive decline and incident dementia. (Alzheimer's & dementia : the journal of the Alzheimer's Association 2025) · cited 20x in the literature
"RetiPhenoAge, a retinal aging biomarker, was derived from retinal photographs using deep-learning... In the UK Biobank (N = 33 495), RetiPhenoAge similarly predicted incident dementia (SHR 1.25, 95% CI 1.09-1.41, p = 0.008)... RetiPhenoAge may provide a non-invasive prognostic screening tool for cognitive decline and dementia." (abstract, methods and results)
pubmed full study (doi)
partial: Prediction of Alzheimer's disease risk factors from retinal images via deep learning: Deve… (Journal of Alzheimer's disease : JAD 2026)
"Several saliency-based scores differed significantly between incident AD and matched controls, suggesting potential overlap between retinal correlates of AD-related risk factors and preclinical AD-associated changes. Conclusions: CFP encodes retinal signatures linked to AD risk factors. Although not diagnostic, DL-derived retinal representations may uncover biologically meaningful risk-related structural changes mirroring the potential AD vulnerability." (abstract, results and conclusions, passage verified)
pubmed full study (doi)

0:32:24 Eric Topoloverstatedhigh

Statins cause severe leg cramps and muscle-related symptoms in patients.

"Some of the data that comes out of these big meta-analyses, which say, "Oh, people don't get any leg cramps." That's not true. You and I know that's not true. People do get severe leg cramps where they can't even sleep at night, you know, uh, and and all sorts of other, you know, leg, uh, and muscle-related symptoms." (said at 0:32:24)

While statin therapy is causally associated with a small excess rate of muscle pain or weakness, the severity and frequency attributed to statins are significantly overstated. A comprehensive individual participant data meta-analysis of 19 large double-blind, placebo-controlled randomized trials (n=123,940) by the Cholesterol Treatment Trialists' Collaboration found that statins caused a small excess of mostly mild muscle symptoms during the first year of treatment (absolute excess of 11 events per 1,000 person-years; rate ratio 1.07). However, after the first year, there was no significant excess risk, and more than 90% of all muscle symptom reports among statin-treated participants were not attributable to the drug, occurring at near-identical rates in the placebo groups (nocebo/drucebo effect and background prevalence). Severe muscle damage (such as rhabdomyolysis or severe myopathy) is very rare.

context: Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis … (Lancet (London, England) 2022) · cited 259x in the literature
"Statin therapy caused a small excess of mostly mild muscle pain. Most (>90%) of all reports of muscle symptoms by participants allocated statin therapy were not due to the statin. The small risks of muscle symptoms are much lower than the known cardiovascular benefits." (abstract, conclusions, passage verified)
pubmed full study (doi)

0:33:00 Eric Topoloverstatedmoderate

Failing to lower LDL cholesterol below 100 mg/dL or 70 mg/dL places individuals at higher risk for dementia.

"if you don't have the LDL lowered to let's say less than 100, less than 70, you're going to be at higher risk for dementia." (said at 0:33:00)

While some observational cohort analyses find that individuals with LDL cholesterol levels below 70 mg/dL have lower rates of incident dementia compared to those with higher levels, randomized controlled trial evidence does not support the claim that actively lowering LDL cholesterol to specific targets (e.g., <100 or <70 mg/dL) reduces dementia risk. Cochrane systematic reviews of randomized trials evaluating statin-induced LDL lowering found no significant reduction in the incidence of dementia or Alzheimer's disease, and trial data from PCSK9 inhibitor studies similarly show no significant effect on dementia outcomes.

contradicts: Statins for the prevention of dementia. (The Cochrane database of systematic reviews 2009) · cited 193x in the literature
"There is good evidence from RCTs that statins given in late life to individuals at risk of vascular disease have no effect in preventing AD or dementia. Biologically it seems feasible that statins could prevent dementia due to their role in cholesterol reduction and initial evidence from observational studies was very promising. Indication bias may have been a factor in these studies however and the evidence from subsequent RCTs has been negative." (abstract, conclusions, passage verified)
pubmed full study (doi)
partial: Low-density lipoprotein cholesterol levels and risk of incident dementia: a distributed ne… (Journal of neurology, neurosurgery, and psychiatry 2025) · cited 10x in the literature
"The LDL-C levels below 70 mg/dL (1.8 mmol/L) were associated with a 26% reduction in the risk of all-cause dementia and a 28% reduction in the risk of ADRD, compared with levels above 130 mg/dL (3.4 mmol/L)." (abstract, results, passage verified)
pubmed full study (doi)
contradicts: Association between PCSK9 targeted therapy and the risk of stroke and dementia: A meta-ana… (The American journal of medicine 2026)
"However, no significant association was observed for the risk of hemorrhagic stroke (OR, 1.16 (95%CI: 0.70-1.93), P = 0.56), transient ischemic attack (OR, 0.98 (95%CI: 0.48-2.06), P = 0.95), dementia (OR, 0.77 (95%CI: 0.14-4.28), P = 0.76), dementia of Alzheimer's type (OR, 0.81 (95%CI: 0.14-4.70), P = 0.82), and Parkinson's disease (OR, 0.82 (95%CI: 0.11-6.37), P = 0.85)." (abstract, results, passage verified)
pubmed full study (doi)

0:38:16 Mark Hyman (host)overstatedlow

NAD+ levels decline by approximately 50% by the time a person reaches middle age.

"The problem is NAD+ levels drop by about 50% by the time you hit middle age." (said at 0:38:16)

The popular claim that human NAD+ levels drop by approximately 50% by middle age originates from small observational studies in specific tissues (notably Massudi et al., 2012, examining human pelvic skin biopsies from 49 participants, which showed an age-dependent reduction). However, applying a universal ~50% decline across the human body by middle age is overstated. Human studies across different tissues and blood show substantial variability: large-scale studies measuring whole-blood NAD+ show modest declines that vary by sex or find that whole-blood NAD+ levels remain largely stable across age cohorts.

supports: Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. (PloS one 2012) · cited 554x in the literature
"A strong negative correlation was observed between NAD(+) levels and age in both males (p = 0.001; r = -0.706) and females (p = 0.01; r = -0.537)." (abstract, results, passage verified)
pubmed full study (doi)
partial: Association of Human Whole Blood NAD + Contents With Aging. (Frontiers in endocrinology 2022) · cited 49x in the literature
"We observed a decline trend of NAD + contents with aging before 50 years in total participants with significant level in 40-49 years old group (β coefficients with 95% confidence interval (95% CI): -1.12 (-2.18, -0.06)), while this trend disappeared after the 50 years." (abstract, results, passage verified)
pubmed full study (doi)
contradicts: Human whole-blood NAD + levels do not vary with age or lifestyle interventions. (Nature metabolism 2026) · cited 3x in the literature
"Using a rigorously validated ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry system that accounts for real-world analytical variability, we quantify NAD + across seven independent human cohorts. We find that whole-blood NAD + levels remain remarkably stable with age" (abstract, results, passage verified)
pubmed full study (doi)

0:42:10 Mark Hyman (host)overstatedhigh

Approximately 20% of statin users experience muscle damage, muscle symptoms, or an increased risk of diabetes.

"And if statins cause side effects, which they do for a lot of people, probably 20% get some muscle damage or some symptoms or increased risk of diabetes" (said at 0:42:10)

The claim that statins cause muscle damage or symptoms in approximately 20% of users significantly overstates the evidence from randomized controlled trials. A large-scale individual participant data meta-analysis of 19 double-blind trials (n=123,940) published by the Cholesterol Treatment Trialists' (CTT) Collaboration found that while 27.1% of statin users reported muscle pain or weakness, 26.6% of placebo users did as well (rate ratio 1.03), indicating that over 90% of reported muscle symptoms were not caused by the statin. The true statin-attributable excess of muscle symptoms was only about 11 events per 1,000 person-years in the first year, and actual muscle damage (clinically significant creatine kinase elevation or rhabdomyolysis) is exceedingly rare. A comprehensive meta-analysis of over 4 million patients found the pooled prevalence of statin intolerance was 9.1% overall and 4.9% in randomized trials, though reaching 17% in unblinded observational cohort studies driven largely by background symptoms and the nocebo effect.

partial: Prevalence of statin intolerance: a meta-analysis. (European heart journal 2022) · cited 468x in the literature
"A total of 176 studies [112 randomized controlled trials (RCTs); 64 cohort studies] with 4 143 517 patients were ultimately included in the analysis. The overall prevalence of SI was 9.1% (95% confidence interval 8.0-10%)... The prevalence of SI in RCTs was significantly lower compared with cohort studies [4.9% (4.0-6.0%) vs. 17% (14-19%)]." (abstract, results, passage verified)
pubmed full study (doi)
contradicts: Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis … (Lancet (London, England) 2022) · cited 259x in the literature
"Among 19 placebo-controlled trials... during a weighted average median follow-up of 4·3 years, 16 835 (27·1%) allocated statin versus 16 446 (26·6%) allocated placebo reported muscle pain or weakness (rate ratio [RR] 1·03; 95% CI 1·01-1·06)... which indicates that only one in 15 ([1·07-1·00]/1·07) of these muscle-related reports by participants allocated to statin therapy were actually due to the statin." (abstract, results)
pubmed full study (doi)

0:49:46 Aseem Malhotraoverstatedhigh

Approximately 1 in 100 (or up to 1 in 50) people prescribed statins develop type 2 diabetes as a result of the medication.

"What else do statins do? They cause insulin resistance. Say 1 in 100 people get type 2 diabetes because of statins. ... Some some studies say 1 in 50, right? Will get type 2 diabetes because of the statin." (said at 0:49:46)

The claim that 1 in 100 (or up to 1 in 50) people develop type 2 diabetes because of statins overstates the excess risk attributable to the medication. In large collaborative meta-analyses of randomized controlled trials, statin therapy was associated with a modest 9% relative increase in incident diabetes (odds ratio 1.09), corresponding to an absolute risk of 1 additional case of diabetes for every 255 patients treated over an average of 4 years (approximately 1 in 255, or ~0.4%). Even when comparing intensive-dose statin therapy to moderate-dose therapy, the number needed to harm per year was 498 (approximately 2.0 additional cases per 1,000 patient-years).

contradicts: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin … (Lancet (London, England) 2010) · cited 2464x in the literature
"Statin therapy was associated with a 9% increased risk for incident diabetes (odds ratio [OR] 1.09; 95% CI 1.02-1.17), with little heterogeneity (I(2)=11%) between trials... Treatment of 255 (95% CI 150-852) patients with statins for 4 years resulted in one extra case of diabetes." (abstract, results)
pubmed full study (doi)
contradicts: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: … (JAMA 2011) · cited 1395x in the literature
"In 5 statin trials with 32,752 participants without diabetes at baseline, 2749 developed diabetes (1449 assigned intensive-dose therapy, 1300 assigned moderate-dose therapy, representing 2.0 additional cases in the intensive-dose group per 1000 patient-years)... As compared with moderate-dose statin therapy, the number needed to harm per year for intensive-dose statin therapy was 498 for new-onset diabetes" (abstract, results, passage verified)
pubmed full study (doi)

Needs context

0:44:21 Aseem Malhotraneeds contextmoderate

Observational cohort studies and randomized controlled trials do not show a clear association between saturated fat consumption and heart disease.

"what I looked at the data, and it was very clear there was no clear association with saturated fat consumption and heart disease. [...] Both observational data and randomized control trials, no benefit like in lowering it, no association, nothing." (said at 0:44:21)

The statement is accurate regarding prospective observational cohort studies and certain mortality outcomes in randomized controlled trials (RCTs), but requires qualification. Meta-analyses of prospective cohort studies find no clear independent association between total dietary saturated fat intake and all-cause mortality, cardiovascular mortality, total coronary heart disease (CHD), or stroke. Similarly, long-term RCTs show no significant reduction in overall or cardiovascular mortality when reducing saturated fat. However, a Cochrane systematic review and meta-analysis of long-term RCTs established that reducing dietary saturated fat intake produces a statistically significant 17% reduction in combined cardiovascular events, particularly when saturated fats are replaced by polyunsaturated fats.

supports: Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, car… (BMJ (Clinical research ed.) 2015) · cited 1441x in the literature
"Saturated fat intake was not associated with all cause mortality (relative risk 0.99, 95% confidence interval 0.91 to 1.09), CVD mortality (0.97, 0.84 to 1.12), total CHD (1.06, 0.95 to 1.17), ischemic stroke (1.02, 0.90 to 1.15), or type 2 diabetes (0.95, 0.88 to 1.03)." (abstract, results, passage verified)
pubmed full study (doi)
partial: Reduction in saturated fat intake for cardiovascular disease. (The Cochrane database of systematic reviews 2020)
"The included long-term trials suggested that reducing dietary saturated fat reduced the risk of combined cardiovascular events by 17% (risk ratio (RR) 0.83; 95% confidence interval (CI) 0.70 to 0.98, 12 trials, 53,758 participants of whom 8% had a cardiovascular event, I² = 67%, GRADE moderate-quality evidence)." (abstract, results, passage verified)
pubmed full study (doi)

Supported by research

0:00:03 Cindy Geyersupportedhigh

Cardiovascular disease is the leading cause of death worldwide and is the leading cause of death among women.

"Yeah, it's still the number one killer around the world, not just here. And it's still the number one killer in women who, you know, they think that it's breast cancer. No, no, this is it." (said at 0:00:03)

Global epidemiological surveillance consistently establishes that cardiovascular disease (CVD) is the leading cause of death globally and specifically the leading cause of mortality among women. According to data from the Global Burden of Disease (GBD) studies, CVD accounted for over 19 million deaths worldwide in 2023, with ischemic heart disease and stroke as the predominant causes. The Lancet Commission on Women and Cardiovascular Disease similarly confirms that CVD is the leading cause of death in women globally, causing far more female deaths than breast cancer or other malignancies.

supports: The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030… (Lancet (London, England) 2021) · cited 1462x in the literature
"Cardiovascular disease is the leading cause of death in women." (abstract, passage verified)
pubmed full study (doi)
supports: Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 C… (Journal of the American College of Cardiology 2025) · cited 510x in the literature
"Cardiovascular diseases (CVDs) are the leading cause of mortality and are among the foremost causes of disability globally." (abstract, passage verified)
pubmed full study (doi)

0:00:31 Cindy Geyersupportedmoderate

Approximately 80% of heart disease and diabetes cases are preventable with diet and lifestyle modifications.

"But we know that 80% of cases of heart disease and diabetes may actually be preventable with diet and lifestyle." (said at 0:00:31)

Large prospective cohort analyses indicate that approximately 80% or more of coronary heart disease and type 2 diabetes cases are attributable to modifiable lifestyle factors, including diet quality, physical activity, body mass index, and non-smoking status. In landmark analyses from the Nurses' Health Study, 82% of coronary events and 91% of type 2 diabetes cases were attributable to non-adherence to a low-risk diet and lifestyle pattern.

supports: Primary prevention of coronary heart disease in women through diet and lifestyle. (The New England journal of medicine 2000) · cited 1810x in the literature
"Eighty-two percent of coronary events in the study cohort (95 percent confidence interval, 58 to 93 percent) could be attributed to lack of adherence to this low-risk pattern." (abstract, results, passage verified)
pubmed full study (doi)
supports: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. (The New England journal of medicine 2001) · cited 2926x in the literature
"A total of 91 percent of the cases of diabetes in this cohort (95 percent confidence interval, 83 to 95) could be attributed to habits and forms of behavior that did not conform to the low-risk pattern." (abstract, results, passage verified)
pubmed full study (doi)

0:02:45 Cindy Geyersupportedmoderate

Fewer than 3% of the United States population meets four core low-risk lifestyle characteristics: non-smoking, 150 minutes of weekly exercise, diet in the top two quintiles of whole foods, and a healthy body fat percentage.

"fewer than 3% of the US population is meeting the core four basic characteristics that predict low risk. And it's a pretty low bar, Mark... It's not smoking... Getting the minimum recommended 150 minutes of exercise a week, eating in the top two quintiles of what's considered a whole foods diet, and having a healthy body fat percentage. Fewer than 3%." (said at 0:02:45)

A nationally representative study of US adults using 2003–2006 National Health and Nutrition Examination Survey (NHANES) data evaluated four healthy lifestyle characteristics: being sufficiently physically active (measured via accelerometry), eating a healthy diet (top 40% of the Healthy Eating Index), being a non-smoker (serum cotinine), and having a recommended body fat percentage (measured via DXA). The authors found that only 2.7% (95% CI, 1.9%–3.4%) of US adults met all four criteria, directly supporting the claim.

supports: Healthy Lifestyle Characteristics and Their Joint Association With Cardiovascular Disease … (Mayo Clinic proceedings 2016) · cited 75x in the literature
"Only 2.7% (95% CI, 1.9%-3.4%) of all adults had all 4 healthy lifestyle characteristics." (abstract, results, passage verified)
pubmed full study (doi)

0:05:42 Cindy Geyersupportedhigh

Standard clinical lipid panels calculate LDL cholesterol via a mathematical formula rather than directly measuring it.

"and they would do a standard cholesterol profile, which interestingly enough calculates your LDL cholesterol, the one we usually think of as being the lousy cholesterol, from a formula, doesn't even really measure it" (said at 0:05:42)

Standard clinical lipid panels typically measure total cholesterol, HDL cholesterol, and triglycerides directly, while calculating LDL cholesterol using mathematical formulas (most commonly the Friedewald equation, or newer alternatives such as Martin-Hopkins or Sampson equations) rather than direct homogeneous assays or reference ultracentrifugation.

supports: Best practice for LDL-cholesterol: when and how to calculate. (Journal of clinical pathology 2023) · cited 56x in the literature
"The lipid profile includes total cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides (TGs) and low-density lipoprotein (LDL)-cholesterol (LDL-C). LDL-C has traditionally been calculated using the Friedewald equation (invalid with TGs greater than 4.5 mmol/L and is based on the assumption that the ratio of TG to cholesterol in very- low-density lipoprotein (VLDL) is 5 when measured in mg /dL). LDL-C can be quantified with a reference method, beta-quantification involving ultracentrifugation and this is unsuitable for routine use." (abstract, passage verified)
pubmed full study (doi)
supports: Low-Density Lipoprotein Cholesterol Gymnastics: Exploring the Advantages and Limitations o… (Journal of personalized medicine 2024) · cited 5x in the literature
"The most commonly used method for low-density lipoprotein cholesterol (LDL-C) estimation is the Friedewald equation, which has notable limitations." (abstract, passage verified)
pubmed full study (doi)

0:09:21 Cindy Geyersupportedmoderate

Large pattern A LDL particles are less prone to oxidative stress, inflammation, and plaque rupture compared to small, dense pattern B LDL particles.

"There's big, fluffy, puffy pattern A LDL cholesterol, which is less easily made into a plaque in the artery, less prone to inflammation and oxidative stress and rupture. So it's a less risky LDL, whereas somebody could have small, dense pattern B LDL, and that's the really risky LDL." (said at 0:09:21)

Published experimental and observational studies demonstrate that large, buoyant LDL particles (predominant in LDL phenotype pattern A) are more resistant to oxidative modification and less strongly associated with pro-inflammatory vascular activation and atherosclerotic progression than small, dense LDL particles (pattern B). Biochemical assays show that resistance to oxidation (measured by lag time before copper-induced oxidation) is significantly longer in larger LDL fractions and shorter in dense fractions, making small dense LDL more susceptible to oxidative modification. Additionally, pattern B profiles are associated with elevated expression of pro-inflammatory cytokines and chemokines and increased cardiovascular risk.

supports: Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory resp… (Atherosclerosis 2009) · cited 85x in the literature
"Peripheral blood mononuclear cells (PBMC) isolated from patients with the predominance of sdLDL (pattern B) had an increased mRNA expression of pro-inflammatory molecules compared to PBMC from patients with the predominance of large LDL (pattern A)" (abstract, results, passage verified)
pubmed full study (doi)
supports: Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subj… (The American journal of medicine 1993) · cited 558x in the literature
"The lag time, a measure of resistance to oxidative modification, was inversely related (p < 0.001) to LDL density in both groups of subjects, without an independent effect of phenotype. The fraction that had the major LDL peak had a shorter lag time (p < 0.05) in pattern B than in pattern A." (abstract, results, passage verified)
pubmed full study (doi)

0:16:29 Cindy Geyersupportedmoderate

According to NHANES data from 2009 to 2016, only 12.2% of American adults were metabolically healthy across key markers including blood pressure, HDL, triglycerides, and fasting glucose.

"So, a recent study was looking at the NHANES data from 2009 to 2016, government surveys... And they found that 12.2% of Americans... 12.2% of Americans were metabolically healthy" (said at 0:16:29)

A widely cited analysis of NHANES data from 2009 to 2016 (n = 8,721 adults) by Araújo et al. (2019) evaluated metabolic health defined by optimal levels of five cardiometabolic risk factors (waist circumference, blood pressure, fasting glucose/HbA1c, triglycerides, and HDL cholesterol without medication). Using the most recent clinical guidelines, only 12.2% (95% CI: 10.9–13.6%) of American adults met the criteria for optimal metabolic health.

supports: Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition E… (Metabolic syndrome and related disorders 2019) · cited 157x in the literature
"Data from the National Health and Nutrition Examination Survey 2009-2016 were analyzed (n = 8721). Using the most recent guidelines, metabolic health was defined as having optimal levels of waist circumference (WC <102/88 cm for men/women), glucose (fasting glucose <100 mg/dL and hemoglobin A1c <5.7%), blood pressure (systolic <120 and diastolic <80 mmHg), triglycerides (<150 mg/dL), and high-density lipoprotein cholesterol (≥40/50 mg/dL for men/women), and not taking any related medication. Changing from ATP III (Adult Treatment Panel III) guidelines to more recent cut points decreased the proportion of metabolically healthy Americans from 19.9% (95% confidence interval [CI]: 18.3-21.5) to 12.2% (95% CI: 10.9-13.6)." (abstract, results, passage verified)
pubmed full study (doi)

0:17:21 Cindy Geyersupportedmoderate

Fewer than one-third of normal-weight individuals in the US are metabolically healthy.

"Fewer than one-third of so-called normal-weight people were metabolically healthy. So, that's another really important message." (said at 0:17:21)

A nationally representative study of US adults using National Health and Nutrition Examination Survey (NHANES) 2009–2016 data (n = 8,721) evaluated optimal cardiometabolic health based on guidelines for waist circumference, fasting glucose/HbA1c, blood pressure, triglycerides, and HDL cholesterol without medication. The study found that less than one-third of normal-weight adults met criteria for optimal metabolic health.

supports: Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition E… (Metabolic syndrome and related disorders 2019) · cited 157x in the literature
"Less than one-third of normal weight adults were metabolically healthy and the prevalence decreased to 8.0% and 0.5% in overweight and obese individuals, respectively." (abstract, results, passage verified)
pubmed full study (doi)

0:19:00 Cindy Geyersupportedmoderate

Ninety percent of Americans with prediabetes are undiagnosed by their physicians.

"when you look at that data and you also look at the parallel data that 90% of Americans with pre-diabetes are not diagnosed by their doctor, right?" (said at 0:19:00)

Surveillance data from the Centers for Disease Control and Prevention (CDC) using the National Health and Nutrition Examination Survey (NHANES) consistently demonstrate that approximately 85% to 90% of US adults meeting clinical criteria for prediabetes are unaware of their condition and have not been told by a health professional that they have it. In NHANES analyses, only 11% to 16% of adults with laboratory-defined prediabetes reported being aware of their diagnosis.

supports: Awareness of prediabetes--United States, 2005-2010. (MMWR. Morbidity and mortality weekly report 2013) · cited 65x in the literature
"This report describes the results of that analysis, which indicated that, during 2009-2010, approximately 11% of those with prediabetes were aware of their condition. Furthermore, during 2005-2010, estimated awareness of prediabetes was <14% across all population subgroups, different levels of health-care access or use, and other factors." (abstract, results, passage verified)
pubmed
supports: Prediabetes awareness is not associated with lower consumption of self-reported added suga… (Annals of epidemiology 2022) · cited 2x in the literature
"Among 3314 adults with prediabetes, 528 reported being aware and 2786 reported being unaware of their condition." (abstract, results, passage verified)
pubmed full study (doi)

0:26:30 Eric Topolsupportedmoderate

GLP-1 receptor agonist drugs reduce systemic inflammation independently of and prior to weight loss.

"We've already seen how GLP-1 drugs do that before any weight loss. So that should work well in people who aren't even obese." (said at 0:26:30)

Randomized clinical trials and translational research demonstrate that GLP-1 receptor agonists exert direct anti-inflammatory effects that occur acutely (even following a single dose) and independently of weight reduction. In human trials, GLP-1 receptor agonism rapidly downregulates reactive oxygen species generation, NF-κB binding, and proinflammatory cytokine expression (including TNF-α, IL-1β, and IL-6) as well as systemic markers such as high-sensitivity C-reactive protein before or in the absence of significant weight loss.

supports: Exenatide exerts a potent antiinflammatory effect. (The Journal of clinical endocrinology and metabolism 2012) · cited 286x in the literature
"After a single injection of exenatide, there was a reduction by 20 ± 7% in free fatty acids, 19 ± 7% in reactive oxygen species generation, 39 ± 11% in nuclear factor-κB binding, 18 ± 9% in TNFα expression, 26 ± 7% in IL-1β expression... Exenatide exerts a rapid antiinflammatory effect at the cellular and molecular level. This may contribute to a potentially beneficial antiatherogenic effect. This effect was independent of weight loss." (abstract, results and conclusions, passage verified)
pubmed full study (doi)
supports: Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benef… (The Journal of clinical investigation 2025) · cited 74x in the literature
"Acute and chronic activation of GLP-1 receptor signaling also reduces systemic and tissue inflammation in mice and humans, through weight loss-dependent and -independent mechanisms, actions that may contribute to the expanding spectrum of clinical benefits ascribed to GLP-1 medicines." (abstract, passage verified)
pubmed full study (doi)

0:26:40 Eric Topolsupportedhigh

GLP-1 receptor agonist medications prevent or improve heart failure with preserved ejection fraction (HFpEF).

"And we've seen how that can prevent heart—preserve ejection fraction heart failure, which is half of all heart failure, right? GLP-1s prevent that." (said at 0:26:40)

Large phase 3 randomized controlled trials have demonstrated that the GLP-1 receptor agonist semaglutide substantially improves symptoms, physical functioning, and clinical outcomes in patients with heart failure with preserved ejection fraction (HFpEF). In the STEP-HFpEF and STEP-HFpEF DM trials, once-weekly semaglutide significantly improved Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS) scores and 6-minute walk distance while reducing body weight compared with placebo in patients with obesity-related HFpEF. Furthermore, a pooled analysis of 3,743 participants across four randomized trials (STEP-HFpEF, STEP-HFpEF DM, SELECT, and FLOW) showed that semaglutide significantly reduced the risk of worsening heart failure events (HR 0.59, 95% CI 0.41–0.82) and composite cardiovascular death or heart failure events (HR 0.69, 95% CI 0.53–0.89).

supports: Semaglutide versus placebo in people with obesity-related heart failure with preserved eje… (Lancet (London, England) 2024) · cited 349x in the literature
"In this prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials, semaglutide was superior to placebo in improving heart failure-related symptoms and physical limitations, and reducing bodyweight in participants with obesity-related heart failure with preserved ejection fraction." (abstract, conclusions, passage verified)
pubmed full study (doi)
supports: Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved … (Lancet (London, England) 2024) · cited 295x in the literature
"In this group of participants with HFpEF, semaglutide reduced the risk of the combined endpoint of cardiovascular death or heart failure events (103 [5·4%] of 1914 in the semaglutide group had events vs 138 [7·5%] of 1829 in the placebo group; hazard ratio [HR] 0·69 [95% CI 0·53-0·89]; p=0·0045). Semaglutide also reduced the risk of worsening heart failure events (54 [2·8%] vs 86 [4·7%]; HR 0·59 [0·41-0·82]; p=0·0019)." (abstract, results, passage verified)
pubmed full study (doi)

0:27:40 Eric Topolsupportedmoderate

AI analysis of retinal images can predict coronary artery calcium scores, stroke risk, and heart disease.

"The retina also tells if you're going to have heart disease or a stroke in advance. It will even tell if you're going to, um, you know, your calcium score of your heart arteries through your retina." (said at 0:27:40)

Published studies confirm that artificial intelligence and deep-learning models applied to retinal fundus photographs can predict coronary artery calcium (CAC) scores, incident cardiovascular disease, and stroke risk. Deep-learning algorithms have demonstrated discrimination of high CAC scores (>100) from zero CAC with an AUROC of approximately 0.83. Furthermore, systematic reviews and cohort studies show that retinal microvascular biomarkers and AI retinal models predict future cardiovascular events (such as myocardial infarction, cardiovascular mortality, and stroke) with predictive accuracy comparable to conventional clinical risk scores.

supports: Predicting High Coronary Artery Calcium Score From Retinal Fundus Images With Deep Learnin… (Translational vision science & technology 2020) · cited 89x in the literature
"A deep learning algorithm for discrimination of no CAC from CACS >100 achieved area under receiver operating curve (AUROC) of 82.3% (79.5%-85.0%) and 83.2% (80.2%-86.3%) using unilateral and bilateral fundus images, respectively, under a 5-fold cross validation setting... Retinal fundus images can be used by deep learning algorithms for prediction of high CACS." (abstract, results and conclusions, passage verified)
pubmed full study (doi)
supports: Retinal imaging for the assessment of stroke risk: a systematic review. (Journal of neurology 2024) · cited 36x in the literature
"Our review identified three models utilizing artificial intelligence algorithms for the analysis of retinal images to predict stroke... Whilst there is strong evidence that retinal imaging features can be used to indicate stroke risk, there is currently no predictive model which significantly outperforms conventional risk scores." (abstract, results and conclusions)
pubmed full study (doi)
supports: Deep-learning prediction of cardiovascular outcomes from routine retinal images in individ… (Cardiovascular diabetology 2025) · cited 37x in the literature
"A deep-learning AI model could accurately predict MACE from routine retinal screening photographs with a comparable performance to traditional clinical risk assessment in a diabetic cohort." (abstract, conclusions, passage verified)
pubmed full study (doi)

0:28:49 Eric Topolsupportedmoderate

Pericoronary arterial inflammation detected by AI analysis on CT angiography in the absence of arterial narrowing is associated with up to a 15-fold increased risk of heart attack.

"No, no, the Cleerly and the other ones in the US don't do this, but this is a a a Oxford, University of Oxford spinout. I think it's called Caristo. They're going to have that available soon. And I went through the data in the book. I mean, they've had multiple papers, but it's striking. If you have inflammation without a narrow, it's, you know, you could have 15-fold risk of a heart attack." (said at 0:28:49)

The claim is supported by large prospective cohort data from University of Oxford researchers and the associated spinout technology (Caristo's AI-assisted perivascular Fat Attenuation Index [FAI] Score). In the ORFAN multicentre longitudinal cohort study published in The Lancet (2024), coronary inflammation measured by FAI Score on coronary CT angiography was evaluated in patients with and without obstructive coronary artery disease. Having high perivascular inflammation across coronary arteries was associated with a 12.6-fold increased risk of major adverse cardiac events (MACE, including myocardial infarction; HR 12.6, 95% CI 8.5–18.6) and a nearly 30-fold increased risk of cardiac mortality, independent of anatomical stenosis.

supports: Non-invasive detection of coronary inflammation using computed tomography and prediction o… (Lancet (London, England) 2018) · cited 1144x in the literature
"The perivascular FAI enhances cardiac risk prediction and restratification over and above current state-of-the-art assessment in coronary CTA by providing a quantitative measure of coronary inflammation." (abstract, conclusions, passage verified)
pubmed full study (doi)
supports: Inflammatory risk and cardiovascular events in patients without obstructive coronary arter… (Lancet (London, England) 2024) · cited 258x in the literature
"Increased FAI Score in all the three coronary arteries had an additive impact on the risk for cardiac mortality (hazard ratio [HR] 29·8 [95% CI 13·9-63·9], p<0·001) or MACE (12·6 [8·5-18·6], p<0·001) comparing three vessels with an FAI Score in the top versus bottom quartile for each artery. FAI Score in any coronary artery predicted cardiac mortality and MACE independently from cardiovascular risk factors and the presence or extent of CAD." (abstract, results, passage verified)
pubmed full study (doi)

0:29:50 Eric Topolsupportedmoderate

Adhering to comprehensive healthy lifestyle practices provides 7 to 10 additional years of life free from major age-related chronic diseases.

"show that if we practice the lifestyle factors that we've been reviewing with the details, um, that we we discussed, that gets us 7 to 10 years of healthy aging without one of these age-related diseases." (said at 0:29:50)

A prospective analysis of 111,562 participants from the Nurses' Health Study and the Health Professionals Follow-Up Study investigated the impact of five low-risk lifestyle factors (a healthy diet, never smoking, ≥30 minutes/day of moderate-to-vigorous physical activity, moderate alcohol consumption, and a normal BMI). At age 50, women adhering to four or five healthy lifestyle factors had 34.4 years of life expectancy free of diabetes, cardiovascular disease, and cancer compared to 23.7 years for those with zero factors (a gain of 10.7 disease-free years). For men, the disease-free life expectancy at age 50 was 31.1 years versus 23.5 years (a gain of 7.6 disease-free years), directly supporting the claim of 7 to 10 additional years of life free from major chronic diseases.

supports: Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 d… (BMJ (Clinical research ed.) 2020) · cited 711x in the literature
"The life expectancy free of diabetes, cardiovascular diseases, and cancer at age 50 was 23.7 years (95% confidence interval 22.6 to 24.7) for women who adopted no low risk lifestyle factors, in contrast to 34.4 years (33.1 to 35.5) for women who adopted four or five low risk factors. At age 50, the life expectancy free of any of these chronic diseases was 23.5 (22.3 to 24.7) years among men who adopted no low risk lifestyle factors and 31.1 (29.5 to 32.5) years in men who adopted four or five low risk lifestyle factors." (abstract, results, passage verified)
pubmed full study (doi)

0:26:26 Eric Topolsupportedhigh

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all heart failure cases.

"preserve ejection fraction heart failure, which is half of all heart failure, right?" (said at 0:26:26)

Large population-based epidemiological studies establish that heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% (roughly 45% to 55%) of all heart failure cases in clinical practice and community cohorts.

supports: Trends in prevalence and outcome of heart failure with preserved ejection fraction. (The New England journal of medicine 2006) · cited 4220x in the literature
"A total of 6076 patients with heart failure were discharged over the 15-year period; data on ejection fraction were available for 4596 of these patients (76 percent). Of these, 53 percent had a reduced ejection fraction and 47 percent had a preserved ejection fraction. The proportion of patients with the diagnosis of heart failure with preserved ejection fraction increased over time and was significantly higher among community patients than among referral patients (55 percent vs. 45 percent)." (abstract, results, passage verified)
pubmed full study (doi)

0:17:59 Mark Hyman (host)supportedhigh

Approximately 50% of American adults have either prediabetes or type 2 diabetes.

"I mean, okay, one out of two Americans has pre-diabetes or type 2 diabetes." (said at 0:17:59)

Nationally representative surveillance data from the National Health and Nutrition Examination Survey (NHANES) support the claim that approximately 50% (one out of two) of American adults have either diabetes or prediabetes. In a landmark NHANES analysis, the unadjusted prevalence among US adults was 14.3% for total diabetes and 38.0% for prediabetes, combining to 52.3%. More recent NHANES analyses (2021–2023) show an age-adjusted diabetes prevalence of 16.3% and prediabetes prevalence of 30.7%, combining to 47.0%.

supports: Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012. (JAMA 2015) · cited 2411x in the literature
"In the overall 2011-2012 population, the unadjusted prevalence (using the hemoglobin A1c, FPG, or 2-hour PG definitions for diabetes and prediabetes) was 14.3% (95% CI, 12.2%-16.8%) for total diabetes, 9.1% (95% CI, 7.8%-10.6%) for diagnosed diabetes, 5.2% (95% CI, 4.0%-6.9%) for undiagnosed diabetes, and 38.0% (95% CI, 34.7%-41.3%) for prediabetes" (abstract, results, passage verified)
pubmed full study (doi)
supports: Trends in Prevalence of Diabetes, Pre-Diabetes, and Cardiometabolic Risk Factor Control Am… (Diabetes, obesity & metabolism 2026)
"The age-adjusted prevalence of total diabetes was stable across the study period: 14.6% (95% CI 13.0%-16.2%) in 2013-2014 and 16.3% (14.6%-18.0%) in 2021-2023... The age-adjusted prevalence of pre-diabetes increased significantly during the study period from 26.4% (23.7%-29.1%) in 2013-2014 to 30.7% (28.4%-33.0%) in 2021-2023" (abstract, results)
pubmed full study (doi)

0:30:23 Mark Hyman (host)supportedhigh

Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein.

"drugs that lower this genetically determined lipoprotein called Lp(a)" (said at 0:30:23)

Lipoprotein(a), or Lp(a), is well-established in the scientific literature as a predominantly genetically determined lipoprotein. Circulating Lp(a) concentrations are largely controlled by variations at the LPA gene locus (including kringle IV type-2 copy number variation and specific single-nucleotide variants), demonstrating an estimated 70% to 90% heritability and remaining largely unaffected by diet and routine lifestyle modifications.

supports: Old and New Lines of Therapy Targeting Lipoprotein(a). (Current atherosclerosis reports 2026) · cited 1x in the literature
"Elevated lipoprotein(a) (Lp[a]) is a prevalent, lifelong, and genetically determined causal cardiovascular risk factor, associated with a wide spectrum of cardiovascular disease..." (abstract, background)
pubmed full study (doi)
supports: Novel Lipoprotein (a) Therapies: A Comprehensive Review. (Current atherosclerosis reports 2026)
"Lipoprotein(a) [Lp(a)] is a genetically determined, independent risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Plasma Lp(a) levels are 70-90% heritable, largely unresponsive to lifestyle changes, and poorly controlled with typical lipid-lowering drugs such as statins and PCSK9 inhibitors." (abstract, background, passage verified)
pubmed full study (doi)

0:31:12 Eric Topolsupportedhigh

Clinical trial data demonstrate that the lower LDL cholesterol is reduced, the greater the cardiovascular protection.

"Well, if you look at all the data, the lower you go, the more protection" (said at 0:31:12)

Large meta-analyses of randomized controlled trials (such as the Cholesterol Treatment Trialists' Collaboration) and individual trial analyses (such as FOURIER and FOURIER-OLE) demonstrate a consistent, log-linear relationship where lower achieved low-density lipoprotein cholesterol (LDL-C) levels yield progressively greater reductions in major cardiovascular events, without a discernible lower threshold for clinical efficacy down to very low LDL-C levels (<20 mg/dL).

supports: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data… (Lancet (London, England) 2010) · cited 6539x in the literature
"Further reductions in LDL cholesterol safely produce definite further reductions in the incidence of heart attack, of revascularisation, and of ischaemic stroke, with each 1·0 mmol/L reduction reducing the annual rate of these major vascular events by just over a fifth. There was no evidence of any threshold within the cholesterol range studied, suggesting that reduction of LDL cholesterol by 2-3 mmol/L would reduce risk by about 40-50%." (abstract, conclusions, passage verified)
pubmed full study (doi)
supports: Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Card… (Circulation 2023) · cited 185x in the literature
"There was a monotonic relationship between lower achieved LDL-C levels-down to very low levels <20 mg/dL-and a lower risk of the primary efficacy end point (composite of cardiovascular death, myocardial infarction, stroke, hospital admission for unstable angina or coronary revascularization) and the key secondary efficacy end point (composite of cardiovascular death, myocardial infarction, or stroke) that persisted after multivariable adjustment (adjusted P trend <0.0001 for each end points)." (abstract, results, passage verified)
pubmed full study (doi)

0:32:45 Eric Topolsupportedhigh

Clinical data do not show that statins cause cognitive impairment or sexual dysfunction.

"Now, with respect to cognitive and, uh, sexual dysfunction, the data really don't show a hit there at all" (said at 0:32:45)

High-certainty evidence from randomized controlled trials and meta-analyses supports the claim that clinical data do not demonstrate a causal link between statin therapy and cognitive impairment or sexual dysfunction. A meta-analysis of individual participant data from 19 double-blind randomized trials encompassing 123,940 individuals found no evidence that statins cause cognitive impairment or other non-hepatic/non-muscular undesirable effects listed in product labels. Furthermore, systematic reviews and meta-analyses of randomized controlled trials evaluating lipid-lowering therapies (including statins) have found no significant association with neurocognitive disorders or global cognitive decline compared to placebo or control groups.

supports: Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Me… (Cardiovascular drugs and therapy 2021) · cited 30x in the literature
"Contemporary lipid-lowering medicines were not associated with cognitive impairment in RCTs. A low LDL-C level did not influence the incidence of cognitive disorder or global cognitive performance." (abstract, conclusions, passage verified)
pubmed full study (doi)
supports: Assessment of adverse effects attributed to statin therapy in product labels: a meta-analy… (Lancet (London, England) 2026) · cited 34x in the literature
"Adverse event data from blinded randomised trials do not support causal relationships between statin therapy and most of the conditions (including cognitive impairment, depression, sleep disturbance, and peripheral neuropathy) listed in product labels as potential undesirable effects." (abstract, conclusions, passage verified)
pubmed full study (doi)

0:32:54 Eric Topolsupportedhigh

Alzheimer's disease accounts for 70% of dementia cases.

"and Alzheimer's, as you know, accounts for 70% of dementia" (said at 0:32:54)

Epidemiological consensus establishes that Alzheimer's disease is the leading cause of dementia, accounting for an estimated 60% to 70% of all dementia cases globally.

supports: Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory b… (Ageing research reviews 2024) · cited 332x in the literature
"Alzheimer's disease (AD) is the most common cause of dementia and accounts for 60-70 % of all cases." (abstract, background, passage verified)
pubmed full study (doi)
supports: Drug repurposing in Alzheimer's disease: Emerging therapeutic strategies and promising can… (Ageing research reviews 2026)
"Alzheimer's disease is a progressive neurodegenerative disorder, and the most common cause of dementia, which causes 60-70 % of cases worldwide" (abstract, background, passage verified)
pubmed full study (doi)

0:34:00 Eric Topolsupportedhigh

High doses of potent statins like rosuvastatin and atorvastatin increase the risk of developing type 2 diabetes.

"because if you take a very potent statin, you have a higher risk of developing type 2 diabetes, right? ... high doses of rosuvastatin, Crestor, or atorvastatin, Lipitor, that could also raise the risk of that person developing type 2 diabetes." (said at 0:34:00)

Large meta-analyses of randomized controlled trials demonstrate that statin therapy—and particularly intensive-dose or high-potency statin regimens such as high-dose atorvastatin and rosuvastatin—is associated with a modest, statistically significant increase in the risk of developing new-onset type 2 diabetes. A 2011 meta-analysis of 5 randomized trials (32,752 participants) comparing intensive-dose to moderate-dose statin therapy found a 12% increased odds of incident diabetes (OR 1.12, 95% CI 1.04–1.22), representing roughly 2.0 additional cases of diabetes per 1,000 patient-years. This dose-dependent diabetogenic effect is well recognized, although guidelines emphasize that cardiovascular benefits generally outweigh this risk in indicated patients.

supports: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin … (Lancet (London, England) 2010) · cited 2464x in the literature
"Statin therapy was associated with a 9% increased risk for incident diabetes (odds ratio [OR] 1.09; 95% CI 1.02-1.17), with little heterogeneity (I(2)=11%) between trials." (abstract, results, passage verified)
pubmed full study (doi)
supports: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: … (JAMA 2011) · cited 1395x in the literature
"In 5 statin trials with 32,752 participants without diabetes at baseline, 2749 developed diabetes (1449 assigned intensive-dose therapy, 1300 assigned moderate-dose therapy, representing 2.0 additional cases in the intensive-dose group per 1000 patient-years)... Odds ratios were 1.12 (95% confidence interval [CI], 1.04-1.22; I(2) = 0%) for new-onset diabetes... In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy." (abstract, results and conclusions, passage verified)
pubmed full study (doi)

0:35:20 Mark Hyman (host)supportedmoderate

Muscle biopsies of individuals taking statins show mitochondrial damage even in the absence of muscle pain or elevated muscle enzymes.

"some of the data I've seen that even in people without muscle pain, even without elevated muscle enzymes, that there's mitochondrial damage on muscle biopsies." (said at 0:35:20)

Published clinical studies evaluating skeletal muscle biopsies (e.g., vastus lateralis) from statin users have demonstrated subclinical perturbations in mitochondrial function and content—including decreased citrate synthase activity, repressed expression of mitochondrial gene pathways, and altered oxidative capacity—even in patients who are asymptomatic (without myalgias) and have normal serum creatine kinase levels.

supports: Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after init… (Translational research : the journal of laboratory and clinical medicine 2015) · cited 6x in the literature
"As expected, simvastatin lowered low-density lipoprotein, but did not induce myalgias or significant increases in serum creatine kinase. However, we found subtle but significant reductions in muscle citrate synthase activity and REE. In addition, quantitative polymerase chain reaction and gene set enrichment analysis of muscle samples revealed significantly repressed gene sets involved in mitochondrial function and induced gene sets involved in remodeling of the extracellular matrix." (abstract, results, passage verified)
pubmed full study (doi)
supports: Statins Affect Skeletal Muscle Performance: Evidence for Disturbances in Energy Metabolism… (The Journal of clinical endocrinology and metabolism 2018) · cited 57x in the literature
"Mitochondrial content tended to be lower in both statin groups than in control subjects. Statin use attenuated substrate use during maximal exercise performance, induced muscle fatigue during repeated muscle contractions, and decreased muscle mitochondrial oxidative capacity. This suggests disturbances in mitochondrial oxidative capacity occur with statin use even in patients without statin-induced muscle complaints." (abstract, results and conclusions, passage verified)
pubmed full study (doi)

0:35:53 Eric Topolsupportedhigh

PCSK9 inhibitor injectable medications are not associated with an increased risk of diabetes.

"the PCSK9 injectable drugs are a winner because they're potent and they have not been associated with diabetes" (said at 0:35:53)

Extensive randomized controlled trial evidence and systematic reviews demonstrate that injectable PCSK9 monoclonal antibodies (such as evolocumab and alirocumab) do not increase the risk of new-onset diabetes or impair glycemic parameters (fasting plasma glucose, HbA1c), unlike statin therapy. A 2022 systematic review and meta-analysis of 32 trials comprising 65,861 participants evaluated this outcome with high certainty evidence and confirmed no increased risk of new-onset diabetes.

supports: Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on n… (Diabetes, obesity & metabolism 2018) · cited 57x in the literature
"Alirocumab and evolocumab, two types of PCSK9-mAb approved by the US Food and Drug Administration and the European Medicines Agency, had no significant impact on NODM and glucose homeostasis, regardless of PCSK9-mAb type, participant characteristics, treatment duration, treatment method and differences in control treatment." (abstract, conclusions, passage verified)
pubmed full study (doi)
supports: Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Ezetimibe on Risk of New-Onse… (Journal of cardiovascular pharmacology and therapeutics 2020) · cited 25x in the literature
"Participants randomized to PCSK9i did not differ from the control patients in diabetes incidence (risk ratio [RR] = 0.99, P = .87, 95% CI = 0.92-1.07)." (abstract, results, passage verified)
pubmed full study (doi)
supports: Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and met… (Heart (British Cardiac Society) 2022) · cited 29x in the literature
"PCSK9 inhibitors do not increase the risk of new-onset diabetes mellitus, neurocognitive events, cataracts or gastrointestinal haemorrhage with high certainty evidence." (abstract, results, passage verified)
pubmed full study (doi)

0:44:24 Aseem Malhotrasupportedhigh

Saturated fat consumption raises LDL cholesterol.

"and we know saturated fat raises LDL cholesterol" (said at 0:44:24)

Extensive randomized controlled trial evidence and systematic reviews consistently show that consumption of saturated fatty acids increases circulating LDL cholesterol (and conversely, reducing dietary saturated fat or replacing it with unsaturated fats lowers total and LDL cholesterol).

supports: Reduction in saturated fat intake for cardiovascular disease. (The Cochrane database of systematic reviews 2020)
"There was little or no effect on cancer mortality, cancer diagnoses, diabetes diagnosis, HDL cholesterol, serum triglycerides or blood pressure, and small reductions in weight, serum total cholesterol, LDL cholesterol and BMI." (abstract, results, passage verified)
pubmed full study (doi)
supports: Impact of Replacement of Individual Dietary SFAs on Circulating Lipids and Other Biomarker… (Advances in nutrition (Bethesda, Md.) 2022) · cited 38x in the literature
"We observed reductions in LDL-cholesterol concentrations after the replacement of palmitic acid (16:0) with UFAs (-0.36 mmol/L; 95% CI: -0.50, -0.21 mmol/L; I2 = 96.0%, n = 18 RCTs) or oleic acid (18:1n-9) (-0.16 mmol/L; 95% CI: -0.28, -0.03 mmol/L; I2 = 89.6%, n = 9 RCTs), with a similar impact on total cholesterol and apoB concentrations." (abstract, results, passage verified)
pubmed full study (doi)

0:44:33 Aseem Malhotrasupportedhigh

Statins exhibit distinct anti-inflammatory and anti-clotting mechanisms independent of cholesterol lowering.

"statins had a separate effect to lower cholesterol, which is their anti-inflammatory and their anti-clotting." (said at 0:44:33)

The claim is supported. Extensive clinical and mechanistic literature confirms that HMG-CoA reductase inhibitors (statins) exert well-established 'pleiotropic' effects independent of their primary low-density lipoprotein (LDL) cholesterol-lowering pathway. By inhibiting the mevalonate pathway and the isoprenylation of small GTP-binding proteins (such as Rho, Ras, and Rac), statins mediate distinct anti-inflammatory effects (e.g., reductions in hs-CRP, proinflammatory cytokines, and leukocyte adhesion) and antithrombotic/anti-clotting effects (e.g., attenuation of tissue factor expression, inhibition of platelet activation and thrombus formation, and modulation of fibrin clot properties).

supports: Pleiotropic Effects of Statins: Focus on Inflammation, Oxidative Stress and Immunomodulati… (Current atherosclerosis reports 2026) · cited 8x in the literature
"Statins exert potent anti-inflammatory, antioxidant and immunomodulatory activities that can be linked to reduced CV events. Statins confer cardio protection via diverse pleiotropic pathways distinct from cholesterol modulation." (abstract, passage verified)
pubmed full study (doi)
supports: Pleiotropic Effects of Statins: Focus on Endothelial Function, Plaque Stability and Thromb… (Current atherosclerosis reports 2026) · cited 1x in the literature
"Statins were found to modulate immune cell phenotypes and endothelial repair pathways, as well as enhance plaque stability, inhibit thrombus formation and fibrin clot characteristics independent of lipids." (abstract, recent findings, passage verified)
pubmed full study (doi)

0:48:30 Aseem Malhotrasupportedmoderate

A systematic review of over 30 randomized controlled trials found no clear relationship between the degree of LDL reduction from cholesterol-lowering drugs and prevention of cardiovascular events.

"So myself and two cardiologists did a systematic review of the totality of drug industry-sponsored trials, by the way, and some diet trials, but many drug industry-sponsored trials, all of the randomized controlled trials on cholesterol-lowering drugs: statins, PCSK9, blah, blah. Was there a clear relationship as you lowered LDL in low-risk and high-risk patients, Mark, okay, over 30 studies, was there a relationship with lowering LDL and preventing cardiovascular events? No." (said at 0:48:30)

The speaker accurately describes the findings of a published systematic review of 35 randomized controlled trials (PMID 32747335), which he co-authored. The review analyzed trials evaluating LDL cholesterol targets across diverse risk populations and concluded that achieving specific LDL target levels through drug therapy did not confer consistent cardiovascular benefit, questioning the direct relationship between LDL-C lowering as a surrogate target and cardiovascular event reduction. A subsequent 2022 systematic review and meta-regression in JAMA Internal Medicine (PMID 35285850) evaluating statin trials similarly concluded that a conclusive relationship between the magnitude of absolute LDL-C reduction and individual clinical outcomes (all-cause mortality, myocardial infarction, stroke) was not established.

supports: Hit or miss: the new cholesterol targets. (BMJ evidence-based medicine 2021) · cited 15x in the literature
"Achieving these cholesterol target levels did not confer any additional benefit in a systematic review of 35 randomised controlled trials." (abstract, results, passage verified)
pubmed full study (doi)
supports: Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relat… (JAMA internal medicine 2022) · cited 112x in the literature
"A conclusive association between absolute reductions in LDL-C levels and individual clinical outcomes was not established, and these findings underscore the importance of discussing absolute risk reductions when making informed clinical decisions with individual patients." (abstract, conclusions, passage verified)
pubmed full study (doi)

0:53:25 Mark Hyman (host)supportedmoderate

A study of emergency room patients presenting with heart attacks showed that two-thirds had diabetes or pre-diabetes upon glucose tolerance testing.

"where they looked basically at a series of patients who came into an emergency room with a heart attack and they did glucose tolerance tests on everybody who came in with a heart attack and they found that two-thirds either had diabetes or pre-diabetes who had a heart attack." (said at 0:53:25)

The host's claim accurately describes the findings of landmark prospective studies evaluating glucometabolic status in patients with acute myocardial infarction (AMI). In the Glucose Tolerance in Patients with Acute Myocardial Infarction (GAMI) study, 181 consecutive patients admitted with acute MI without previously diagnosed diabetes were evaluated with an oral glucose tolerance test (OGTT). At hospital discharge, 35% had impaired glucose tolerance (pre-diabetes) and 31% had previously undiagnosed diabetes mellitus, totaling 66% (two-thirds) of the cohort. At three months post-discharge, 40% had impaired glucose tolerance and 25% had diabetes, maintaining the overall two-thirds prevalence of dysglycemia.

supports: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis … (Lancet (London, England) 2002) · cited 1125x in the literature
"58 of 164 (35%, 95% CI 28-43) and 58 of 144 (40%, 32-48) individuals had impaired glucose tolerance at discharge and after 3 months, respectively, and 51 of 164 (31%, 24-38) and 36 of 144 (25%, 18-32) had previously undiagnosed diabetes mellitus." (abstract, results, passage verified)
pubmed full study (doi)
supports: Oral glucose tolerance test: a reliable tool for early detection of glucose abnormalities … (Diabetes care 2008) · cited 91x in the literature
"At discharge, 34, 31, and 34% were classified as having normal glucose tolerance, impaired glucose tolerance (IGT), or type 2 diabetes, respectively" (abstract, results, passage verified)
pubmed full study (doi)

0:54:05 Mark Hyman (host)supportedmoderate

Approximately 93% of Americans have obesity, pre-diabetes, or cardiometabolic dysfunction.

"pre-diabetes or metabolic dysfunction, which is basically in America 93% of Americans" (said at 0:54:05)

A nationally representative study of 55,081 U.S. adults using National Health and Nutrition Examination Survey (NHANES) data from 1999 to 2018 evaluated cardiometabolic health across five components: adiposity (BMI and waist circumference), blood glucose, blood lipids, blood pressure, and clinical cardiovascular disease. In 2017–2018, only 6.8% (95% CI: 5.4%–8.1%) of U.S. adults had optimal levels across all five components without medication, meaning approximately 93.2% of American adults had suboptimal cardiometabolic health.

supports: Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018. (Journal of the American College of Cardiology 2022) · cited 171x in the literature
"In 2017-2018, only 6.8% (95% CI: 5.4%-8.1%) of U.S. adults had optimal cardiometabolic health, declining from 1999-2000 (P trend = 0.02)." (abstract, results, passage verified)
pubmed full study (doi)

0:54:40 Aseem Malhotrasupportedlow

In the Framingham Heart Study, after age 50, mortality increased as total cholesterol dropped.

"another thing that was interesting from Framingham which wasn't well publicized is that when after people hit 50 years old, as their cholesterol dropped, their mortality increased." (said at 0:54:40)

Published analyses of the Framingham Heart Study support the statement. In a 30-year follow-up analysis of Framingham participants published in JAMA (1987), researchers reported that for individuals over age 50, falling total cholesterol levels over a 14-year period were associated with an 11% increase in overall mortality and a 14% increase in cardiovascular mortality for every 1 mg/dL per year decrease in cholesterol. A subsequent 1993 analysis confirmed that total cholesterol was negatively associated with all-cause mortality at age 80 and non-significantly or negatively associated in middle-to-older age groups. The original study authors noted that this observational association in older adults is confounded by reverse causality, wherein developing chronic illnesses cause cholesterol levels to drop prior to death.

context: Cholesterol and mortality. 30 years of follow-up from the Framingham study. (JAMA 1987) · cited 974x in the literature
"After age 50 years the association of mortality with cholesterol values is confounded by people whose cholesterol levels are falling--perhaps due to diseases predisposing to death." (abstract, conclusions, passage verified)
pubmed full study (doi)
supports: Total serum cholesterol levels and mortality risk as a function of age. A report based on … (Archives of internal medicine 1993) · cited 120x in the literature
"The relationship between total cholesterol level and all-cause mortality was positive (ie, higher cholesterol level associated with higher mortality) at age 40 years, negative at age 80 years, and negligible at ages 50 to 70 years." (abstract, results, passage verified)
pubmed

0:54:26 Aseem Malhotrasupportedlow

A 2016 systematic review of observational cohort studies in people over age 60 found an inverse association between LDL cholesterol and all-cause mortality.

"2016, and the reason we did this, me and a number of international scientists, we decided to do a systematic review of observational data looking at people over 60. ... but what was surprising was there was an inverse association with LDL cholesterol and all-cause mortality. In other words, statistically, if you're over 60, the higher LDL, the less likely you are to die." (said at 0:54:26)

A 2016 systematic review by Ravnskov et al. (published in BMJ Open) evaluated 19 cohort studies comprising 30 cohorts and 68,094 participants aged 60 years and older. The authors reported an inverse association between LDL cholesterol and all-cause mortality in 16 of the 28 cohorts where all-cause mortality was recorded (representing 92% of analyzed participants), with no association found in the remaining cohorts. Because the underlying evidence base consists of observational cohort studies susceptible to reverse causation (e.g., frailty, terminal illness, or malnutrition lowering cholesterol levels prior to death) and residual confounding, the certainty of evidence for this observational association is low.

supports: Lack of an association or an inverse association between low-density-lipoprotein cholester… (BMJ open 2016) · cited 358x in the literature
"Inverse association between all-cause mortality and LDL-C was seen in 16 cohorts (in 14 with statistical significance) representing 92% of the number of participants, where this association was recorded. In the rest, no association was found." (abstract, results, passage verified)
pubmed full study (doi)

0:55:50 Aseem Malhotrasupportedhigh

Low cholesterol levels are associated with an increased incidence of cancer.

"And we also know there is an association—I'll use this word, an association, right? Not definitely causal—between low cholesterol and cancer." (said at 0:55:50)

Epidemiological cohort studies have repeatedly demonstrated an observational association between low serum total cholesterol levels and an increased incidence or mortality of cancer. However, extensive research—including randomized intervention trials, long-term prospective cohorts, and Mendelian randomization analyses—indicates that this relationship is non-causal. Instead, the inverse association is largely explained by reverse causality (subclinical, undiagnosed malignancies consuming or suppressing serum lipids prior to diagnosis) and confounding factors such as underlying liver dysfunction or low albumin levels. Because the speaker explicitly qualified the statement as an observational association rather than a causal link, the statement accurately reflects the epidemiological evidence.

supports: Low serum cholesterol, cancer and other noncardiovascular disorders. (Atherosclerosis 1992) · cited 30x in the literature
"A review of the evidence from ecological, cross-cultural comparisons, prospective epidemiological cohort studies and intervention trials provides no indication for a cause-and-effect association between low serum cholesterol or serum cholesterol lowering and the risk of cancer, except possibly at very low levels." (abstract, passage verified)
pubmed full study (doi)
supports: Liver diseases and low serum albumin as potential confounders in the association between l… (Journal of clinical lipidology 2026)
"While cholesterol-lowering trials have consistently demonstrated cardiovascular disease (CVD) benefits, some observational studies showed an elevated mortality risk from all-cause, CVD, and cancer in those with low total cholesterol (TC)." (abstract, background, passage verified)
pubmed full study (doi)
supports: Review of the epidemiological evidence for a possible relationship between hypocholesterol… (Cancer research 1983) · cited 57x in the literature
"the available data do not substantiate any direct cause and effect relationship between low blood cholesterol levels and cancer. Rather, the data suggest that low cholesterol levels may serve as a "marker," possibly genetic, and in only small numbers of male individuals in any given population" (abstract, conclusions, passage verified)
pubmed

0:56:40 Mark Hyman (host)supportedhigh

Statins induce endothelial nitric oxide synthase expression, dilating blood vessels and reducing vascular inflammation.

"So they, for example, they induce nitric oxide synthase, which dilates your blood vessels and reduces inflammation and helps your lining of your blood vessels." (said at 0:56:40)

Extensive pharmacological and vascular research demonstrates that statins upregulate and activate endothelial nitric oxide synthase (eNOS). This occurs via cholesterol-independent (pleiotropic) mechanisms, primarily through the inhibition of isoprenoid synthesis and Rho/ROCK signaling, as well as activation of the PI3K/Akt pathway. The resulting increase in endothelial nitric oxide bioavailability promotes vasodilation, reduces vascular inflammation, and improves overall endothelial function.

supports: Statins: potent vascular anti-inflammatory agents. (International journal of clinical practice. Supplement 2004) · cited 24x in the literature
"Statins exert their pleiotropic effects, in part, by improving endothelial function via up-regulation of endothelial nitric oxide synthase enzyme activity." (abstract, passage verified)
pubmed full study (doi)
supports: Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of stat… (Journal of molecular and cellular cardiology 2012) · cited 90x in the literature
"The upregulation of eNOS by statins is mediated through inhibition of synthesis of isoprenoids and subsequent prevention of isoprenylation of small GTPase Rho, whereas statin-induced activation of eNOS is mediated through activation of phosphotidylinositol-3-kinase (PI3K)/protein kinase B (PKB/Akt) signals. Additionally, statins enhance eNOS activation by abrogating caveolin-1 expression in vascular endothelium. In light of this view-point, we suggest in this review that eNOS upregulation and activation, in part, could play a fundamental role in the cardiovascular defensive potential of statins." (abstract, passage verified)
pubmed full study (doi)

0:32:20 Mark Hyman (host)supportedhigh

Sex steroid hormones, including testosterone, are biochemically synthesized from cholesterol.

"sex hormones, which is what your testosterone is made from, is cholesterol." (said at 0:32:20)

The host's statement that sex steroid hormones, including testosterone, are biochemically synthesized from cholesterol is fully supported by established biochemical literature. Cholesterol serves as the initial precursor for all steroid hormones (including testosterone, progesterone, estrogens, cortisol, and aldosterone). The enzymatic pathway begins with the transport of cholesterol into mitochondria (facilitated by the steroidogenic acute regulatory [StAR] protein) and its cleavage into pregnenolone by the enzyme CYP11A1, which is subsequently converted through enzymatic steps into testosterone and other sex steroids.

supports: Cholesterol Contributes to Male Sex Differentiation Through Its Developmental Role in Andr… (Endocrinology 2021) · cited 14x in the literature
"Two specialized functions of cholesterol during fetal development include serving as a precursor to androgen synthesis and supporting hedgehog (HH) signaling activity." (abstract, background, passage verified)
pubmed full study (doi)
supports: VDR promotes testosterone synthesis in mouse Leydig cells via regulation of cholesterol si… (Genes & genomics 2023) · cited 18x in the literature
"In the early stage of steroidogenesis, cholesterol is converted to pregnenolone (precursor of most steroid hormones) by cholesterol side-chain lyase (CYP11A1), which eventually synthesizes the male hormone testosterone." (abstract, background, passage verified)
pubmed full study (doi)
supports: The multifaceted landscape of the StAR protein in steroid biosynthesis: from development t… (The Journal of endocrinology 2025) · cited 4x in the literature
"Cholesterol is the precursor of all steroid hormones." (abstract, background, passage verified)
pubmed full study (doi)

0:46:54 Aseem Malhotrasupportedhigh

The Framingham Heart Study began longitudinal data collection in Massachusetts in 1948.

"So these are the Framingham studies that, uh, you know, started in Massachusetts in 1948 and went over decades looking at thousands of people" (said at 0:46:54)

The statement is accurate. The Framingham Heart Study is the longest-running cardiovascular epidemiological cohort study; it was established in 1948 in Framingham, Massachusetts, collecting longitudinal data over multiple generations across several decades.

supports: Framingham Heart Study (Journal of the American College of Cardiology 2021) · cited 93x in the literature
"The Framingham Heart Study is the longest-running cardiovascular epidemiological study, starting in 1948." (abstract, passage verified)
openalex full study (doi)

0:55:08 Aseem Malhotrasupportedlow

A 2016 systematic review of observational cohort studies found no association between LDL cholesterol levels and cardiovascular disease in individuals aged 60 and older.

"So we looked at: was there first of all any association if you're over 60 with LDL cholesterol and heart disease? We found none." (said at 0:55:08)

A 2016 systematic review by Ravnskov and colleagues evaluated 19 cohort studies (30 cohorts, 68,094 individuals aged 60 and older) examining LDL cholesterol and mortality outcomes. Regarding cardiovascular mortality across 9 cohorts where it was assessed, seven cohorts found no association with LDL-C levels, and two cohorts found cardiovascular mortality was highest in the lowest LDL-C quartile. For all-cause mortality, an inverse association or lack of association was observed. Because this evidence is derived entirely from observational cohort studies prone to reverse causation and residual confounding, the certainty of evidence is low.

supports: Lack of an association or an inverse association between low-density-lipoprotein cholester… (BMJ open 2016) · cited 358x in the literature
"In two cohorts, CV mortality was highest in the lowest LDL-C quartile and with statistical significance; in seven cohorts, no association was found." (abstract, results, passage verified)
pubmed full study (doi)

No source found (not proven false)

0:52:29 Mark Hyman (host)unverifiedvery low

Less than 1% of commercial lab blood panels ordered through Quest Diagnostics include fasting insulin measurement.

"I was talking to the lab director at Quest Laboratories. He said, "What percent of your tests you get to come in are measuring insulin, which is, I think, one of the most important things you need to know about your biomarkers?" And he was like, "Less than 1%."" (said at 0:52:29)

No published record matching the claim that less than 1% of commercial lab blood panels ordered through Quest Diagnostics include fasting insulin measurement was located; this does not prove the claim false. The claim describes an informal conversation with an unnamed laboratory director, and official commercial laboratory order volume statistics for routine fasting insulin testing have not been published in the peer-reviewed medical literature.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.